Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real-world outcomes in T-cell/histiocyte-rich large B-cell lymphoma: Insights from the largest u.S. cohort to date

View Full Paper
Ask AI
Bookmark
Share

Authors

LRLaura Reyes-UribeThe University of Texas MD Anderson Cancer CenterJMJoel MichalekThe University of Texas Health Science Center at San AntonioLBLeyla BojaniniTexas A&M University – San Antonio

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows similar overall survival in T-cell/histiocyte-rich large B-cell lymphoma across cancer care settings, suggesting standardized care may bridge disparities.

Key Points

  • To evaluate demographic, socioeconomic, and survival differences in T-cell/histiocyte-rich large B-cell lymphoma treatment across different cancer programs.
  • Retrospective analysis of THRLBCL patients in the United States from 2004 to 2022
  • Comparison of demographic, clinical, and survival data between Academic Cancer Programs and Community Cancer Programs
  • Use of Kaplan-Meier and Cox proportional hazards models for survival analysis
  • 1,938 patients diagnosed with THRLBCL were analyzed, with about 46% treated at Academic Cancer Programs
  • Overall survival rates after 2, 5, and 10 years were similar for both ACPs and CCPs
  • ACPs treated a younger and more racially diverse population with advanced-stage disease more common among them

Cite This Study

Reyes-Uribe et al. (2025) studied this question.

synapsesocial.com/papers/69362f764fa91c937236e407https://doi.org/10.1182/blood-2025-3662
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The academic center effect: Better outcomes for patients with DLBCL2025
  2. 2Abstract 4823: Survival outcomes similar in T-cell/histiocyte-rich large B-cell lymphoma between Hispanics and non-Hispanics within the United States2024
  3. 3Patients with burkitt's lymphoma have a better survival probability if treated in an academic cancer program2025
  4. 4Academic cancer programs deliver improved long-term survival in nodular lymphocyte predominant Hodgkin lymphoma: Insights from 7,000+ United States patients2025
  5. 5Association of survival benefit with treatment at academic cancer programs in older adults with PTCL: A National Cancer Database analysis.2026